Amgenvs.Gilead Sciences
AMGN vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 1.2× larger than Gilead Sciences by market cap; year to date, Amgen leads (+23.0% vs +19.6%).
Side by side
| AMGN | GILD | |
|---|---|---|
| Market cap | $223B | $180B |
| Price | $407.44 | $147.10 |
| Today | −1.4% | +0.2% |
| Return YTD | +23.0% | +19.6% |
| Return 1Y | +36.9% | +25.7% |
| Since June 26, 2026 | +13.7% | +15.0% |
| P/E | 25.5 | — |
| P/S | 5.9 | 5.9 |
| P/B | 19.1 | 15.2 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More AMGN & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.